公开(公告)号：US07582653B2

公开(公告)日：2009-09-01

申请号：US11812251

申请日：2007-06-15

申请人： Sangita ,  Atul Kumar ,  Man Mohan Singh ,  Girish Kumar Jain ,  Puvvada Sri Ramanchandra Murthy ,  Suprabhat Ray

发明人： Sangita ,  Atul Kumar ,  Man Mohan Singh ,  Girish Kumar Jain ,  Puvvada Sri Ramanchandra Murthy ,  Suprabhat Ray

IPC分类号： A61K31/4453 ,  A61K31/40 ,  A61K31/135 ,  A61K31/12 ,  C07D295/04 ,  C07C317/14 ,  C07C321/00

CPC分类号： C07D295/088 ,  C07C317/22 ,  C07C317/24 ,  C07C323/19 ,  C07C323/22 ,  C07C323/25

摘要： Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.

摘要翻译： 新的巯基苯基萘基甲烷化合物，其药学上可接受的盐和组合物可用于预防或治疗与与雌激素依赖性疾病或与骨质疏松症，骨丢失，骨形成，心血管疾病，神经变性疾病，绝经障碍相关的综合征相关的各种医学适应症 ，生理障碍，糖尿病，前列腺癌，乳腺癌，子宫癌，宫颈癌和结肠癌，威胁或习惯性流产，肥胖，卵巢发育或功能，产后泌乳和抑郁症。

公开(公告)号：US07250446B2

公开(公告)日：2007-07-31

申请号：US10809845

申请日：2004-03-26

申请人： Sangita ,  Atul Kumar ,  Man Mohan Singh ,  Girish Kumar Jain ,  Puvvada Sri Ramanchandra Murthy ,  Suprabhat Ray

发明人： Sangita ,  Atul Kumar ,  Man Mohan Singh ,  Girish Kumar Jain ,  Puvvada Sri Ramanchandra Murthy ,  Suprabhat Ray

IPC分类号： A61K31/18 ,  C07C313/00 ,  C07C315/00

CPC分类号： C07D295/088 ,  C07C317/22 ,  C07C317/24 ,  C07C323/19 ,  C07C323/22 ,  C07C323/25

摘要： Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.

摘要翻译： 新的巯基苯基萘基甲烷化合物，其药学上可接受的盐和组合物可用于预防或治疗与与雌激素依赖性疾病或与骨质疏松症，骨丢失，骨形成，心血管疾病，神经变性疾病，绝经障碍相关的综合征相关的各种医学适应症 ，生理障碍，糖尿病，前列腺癌，乳腺癌，子宫癌，宫颈癌和结肠癌，威胁或习惯性流产，肥胖，卵巢发育或功能，产后泌乳和抑郁症。

公开(公告)号：US07427686B2

公开(公告)日：2008-09-23

申请号：US10677116

申请日：2003-09-30

申请人： Sangita ,  Atul Kumar ,  Man Mohan Singh ,  Suprabhat Ray ,  Girish Kumar Jain

发明人： Sangita ,  Atul Kumar ,  Man Mohan Singh ,  Suprabhat Ray ,  Girish Kumar Jain

IPC分类号： C07D311/00

CPC分类号： C07D311/58

摘要： The present invention relates to compounds of the formula I in which substituents R2 and R3 are arranged in trans-configuration: wherein: R1 is H or C1-C6 alkyl; C3-C7 cycloalkyl; R2 is phenyl, optionally substituted with 1 to 5 substituents independently selected from the group comprising OH, C1-C6-alkyl, halogen, nitro, cyano, SH, SR4, trihalo-C1-C6-alkyl, C1-C6-alkoxy and phenyl, wherein R4 is C1-C6 alkyl; R3 is phenyl substituted with OR5 wherein R5 has the formula (II), (III) or (IV) wherein Y is chosen from NHR4, NR42, NHCOR4, NHSO2R4, CONHR4, CONR4, CONR42, COOH, COOR4, SO2R4, SOR4, SONHR4, SONR42, a C3-C7 heterocyclic ring, saturated or unsaturated, containing one or two heteroatoms independently selected from the group consisting of O, S and N, optionally being substituted with 1 to 3 substituents independently selected from the group comprising H, OH, halogen, nitro, cyano, SH, SR4, trihalo-C1-C6-alkyl, C1-C6-alkyl and C1-C6-alkoxy, preferably NHR4, NR24, or a nitrogen heterocycle, wherein R4 is as defined above, and the esters, ethers, and salts of the compounds of formula I, optionally along pharmaceutically acceptable excipients, a process for the preparation of the same, and a method of preventing and/or treating estrogen-related disease conditions in a subject using compounds of formula 1, or its salts, optionally along with pharmaceutically acceptable excipients.

公开(公告)号：US20120003273A1

公开(公告)日：2012-01-05

申请号：US13127913

申请日：2009-05-14

申请人： Atul Goel ,  Amit Kumar ,  Sumit Chaurasia ,  Divya Singh ,  Abnish Kumar Gautam ,  Rashmi Pandey ,  Ritu Trivedi ,  Man Mohan Singh ,  Naibedya Chattopadhyay ,  Lakshmi Manickavasagam ,  Girish Kumar Jain ,  Anil Kumar Dwivedi

发明人： Atul Goel ,  Amit Kumar ,  Sumit Chaurasia ,  Divya Singh ,  Abnish Kumar Gautam ,  Rashmi Pandey ,  Ritu Trivedi ,  Man Mohan Singh ,  Naibedya Chattopadhyay ,  Lakshmi Manickavasagam ,  Girish Kumar Jain ,  Anil Kumar Dwivedi

IPC分类号： A61K31/352 ,  C07D311/36 ,  A61P19/08 ,  A61K31/4453 ,  A61P19/10 ,  C07D493/04 ,  A61K9/00

CPC分类号： C07D493/04 ,  C07D311/36

摘要： The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted aroyl, optionally substituted acyloxy, optionally substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro but not limited to this; wherein R1R2 or R2R3 or R6R7 may be connected and form either a five membered ring or a six membered ring such as optionally substituted furan, optionally substituted dihydrofuran, optionally substituted pyran; or may be connected through a methylenedeoxy moiety; wherein X is selected from the units consisting of optionally a ketone group, optionally a methylene group, optionally substituted methylene group, optionally substituted alkene; wherein Y and Z is selected from the units consisting of CH, C—OH, C-Me, C—OMe with the proviso that bond between Y and Z is a single bond; Wherein Y and Z may be a carbon atom with the proviso that bond between Y and Z is a double bond. The compounds of the general formula is useful for the prevention and treatment of bone related disorders.

摘要翻译： 本发明涉及具有通式（I）的新型取代的苯并呋喃和其相关化合物，其盐和手性的非手性衍生物; 其中R1，R2，R3，R4，R5，R6，R7，R8独立地选自氢，任选取代的烷基，任选取代的烯基，任选取代的烷氧基，任选取代的芳基，任选取代的杂芳基，任选取代的烷硫基， 任选取代的氨基，任选取代的酰基氨基，任选取代的芳基氨基，任选取代的酰基硫基，任选取代的酰基，任选取代的芳酰基，任选取代的酰氧基，任选取代的硫代酰氨基，卤素，腈，酯，羟基，巯基，三氟化碳，硝基，但不限于此 ; 其中R1R2或R2R3或R6R7可以连接并形成五元环或六元环，例如任选取代的呋喃，任选取代的二氢呋喃，任选取代的吡喃; 或可以通过亚甲二氧基部分连接; 其中X选自由任选的酮基，任选的亚甲基，任选取代的亚甲基，任选取代的烯烃组成的单元; 其中Y和Z选自由CH，C-OH，C-Me，C-OMe组成的单元，条件是Y和Z之间的键是单键; 其中Y和Z可以是碳原子，条件是Y和Z之间的键是双键。 通式的化合物可用于预防和治疗骨相关疾病。

公开(公告)号：US08686028B2

公开(公告)日：2014-04-01

申请号：US13127913

申请日：2009-05-14

申请人： Atul Goel ,  Amit Kumar ,  Sumit Chaurasia ,  Divya Singh ,  Abnish Kumar Gautam ,  Rashmi Pandey ,  Ritu Trivedi ,  Man Mohan Singh ,  Naibedya Chattopadhyay ,  Lakshmi Manickavasagam ,  Girish Kumar Jain ,  Anil Kumar Dwivedi

发明人： Atul Goel ,  Amit Kumar ,  Sumit Chaurasia ,  Divya Singh ,  Abnish Kumar Gautam ,  Rashmi Pandey ,  Ritu Trivedi ,  Man Mohan Singh ,  Naibedya Chattopadhyay ,  Lakshmi Manickavasagam ,  Girish Kumar Jain ,  Anil Kumar Dwivedi

IPC分类号： A61K31/352 ,  A61K31/4453 ,  C07D311/36 ,  C07D493/04

CPC分类号： C07D493/04 ,  C07D311/36

摘要： The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted aroyl, optionally substituted acyloxy, optionally substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro but not limited to this; wherein R1R2 or R2R3 or R6R7 may be connected and form either a five membered ring or a six membered ring such as optionally substituted furan, optionally substituted dihydrofuran, optionally substituted pyran; or may be connected through a methylenedeoxy moiety; wherein X is selected from the units consisting of optionally a ketone group, optionally a methylene group, optionally substituted methylene group, optionally substituted alkene; wherein Y and Z is selected from the units consisting of CH, C—OH, C-Me, C—OMe with the proviso that bond between Y and Z is a single bond; Wherein Y and Z may be a carbon atom with the proviso that bond between Y and Z is a double bond. The compounds of the general formula is useful for the prevention and treatment of bone related disorders.

摘要翻译： 本发明涉及具有通式（I）的新型取代的苯并呋喃和其相关化合物，其盐和手性的非手性衍生物; 其中R1，R2，R3，R4，R5，R6，R7，R8独立地选自氢，任选取代的烷基，任选取代的烯基，任选取代的烷氧基，任选取代的芳基，任选取代的杂芳基，任选取代的烷硫基， 任选取代的氨基，任选取代的酰基氨基，任选取代的芳基氨基，任选取代的酰基硫基，任选取代的酰基，任选取代的芳酰基，任选取代的酰氧基，任选取代的硫代酰氨基，卤素，腈，酯，羟基，巯基，三氟化碳，硝基，但不限于此 ; 其中R1R2或R2R3或R6R7可以连接并形成五元环或六元环，例如任选取代的呋喃，任选取代的二氢呋喃，任选取代的吡喃; 或可以通过亚甲二氧基部分连接; 其中X选自由任选的酮基，任选的亚甲基，任选取代的亚甲基，任选取代的烯烃组成的单元; 其中Y和Z选自由CH，C-OH，C-Me，C-OMe组成的单元，条件是Y和Z之间的键是单键; 其中Y和Z可以是碳原子，条件是Y和Z之间的键是双键。 通式的化合物可用于预防和治疗骨相关疾病。

公开(公告)号：US08225283B2

公开(公告)日：2012-07-17

申请号：US11862171

申请日：2007-09-26

申请人： Man Mohan Singh ,  Sai Zeng ,  Jose Gomes ,  Ioana Boier-Martin

发明人： Man Mohan Singh ,  Sai Zeng ,  Jose Gomes ,  Ioana Boier-Martin

IPC分类号： G06F9/44

CPC分类号： G06F8/71

摘要： A computer-implemented method supporting collaborative product development. A plurality of artifacts associated with the collaborative product development is maintained under revision control in a first repository. Each artifact has a plurality of lifecycle states and each artifact is associated with a first finite state machine (FSM) that defines lifecycle state transitions for the artifacts. A plurality of artifact tuples associated with the collaborative product development is maintained under revision control in a second repository. At least one artifact tuple is comprised of at least one access information providing access to at least one of said plurality of artifacts in the first repository. Each artifact tuple has a plurality of lifecycle states and each artifact tuple is associated with a second finite state machine (FSM) that defines lifecycle state transitions for the artifact tuples. There exists a set of lifecycle state transition mappings which maps all valid lifecycle state transitions for an artifact with desired lifecycle state transitions for an artifact tuple and all valid lifecycle state transitions for an artifact tuple with desired lifecycle state transitions for an artifact. A workflow process relating to an evolution of an artifact or artifact tuple is expressed through sequencing of one or more members of the said lifecycle state transition mappings set.

摘要翻译： 支持协同产品开发的计算机实现方法。 与协作产品开发相关联的多个工件在第一仓库中被维护在版本控制下。 每个工件具有多个生命周期状态，并且每个工件与定义工件的生命周期状态转换的第一有限状态机（FSM）相关联。 与协作产品开发相关联的多个伪像元组在第二存储库中被维护在版本控制下。 至少一个工件元组由至少一个访问信息组成，提供对第一存储库中的所述多个工件中的至少一个工件的访问。 每个工件元组具有多个生命周期状态，并且每个工件元组与定义人造元组的生命周期状态转换的第二有限状态机（FSM）相关联。 存在一组生命周期状态转换映射，它将工件的所有有效生命周期状态转换与工件元组的所需生命周期状态转换和工件的所有生命周期状态转换的工件元组的所有有效生命周期状态转换进行映射。 通过对所述生命周期状态转换映射集合中的一个或多个成员的排序来表示与工件或伪像元组的演进有关的工作流过程。

公开(公告)号：US20090221690A1

公开(公告)日：2009-09-03

申请号：US12281098

申请日：2007-02-27

申请人： Rakesh Maurya ,  Geetu Singh ,  Pandruvada Subramanyam Narayan Murthy ,  Sandhya Mehrotra ,  Divya Singh ,  Biju Bhargava ,  Man Mohan Singh

发明人： Rakesh Maurya ,  Geetu Singh ,  Pandruvada Subramanyam Narayan Murthy ,  Sandhya Mehrotra ,  Divya Singh ,  Biju Bhargava ,  Man Mohan Singh

IPC分类号： A61K31/352 ,  C07D311/04

CPC分类号： A61K36/48 ,  A61K31/35 ,  A61K31/352

摘要： Osteoporosis is one of the major problems in our aging society. Osteoporosis results in bone fracture in older members of the population, especially in post-menopausal women. In traditional medicine, there are many natural crude drugs that have the potential for use to treat bone diseases. So far, there is no report in literature on anti-osteoporosis (bone forming) activity of Butea species. It was thought to study the anti-osteoporotic activity of this plant. Thus, the present invention provides a pharmaceutical composition from the extracts of Butea monosperma for prevention or treatment of bone disorders, process of preparation and use thereof.

摘要翻译： 骨质疏松症是老龄化社会的主要问题之一。 骨质疏松症导致老年人群中的骨折，特别是绝经后妇女。 在传统医学中，有许多天然生物药物有潜力用于治疗骨骼疾病。 迄今为止，还没有有关Butea物种抗骨质疏松（骨形成）活性的文献报道。 被认为是研究这种植物的抗骨质疏松活性。 因此，本发明提供了一种用于预防或治疗骨骼疾病的白芍提取物的药物组合物，其制备方法和用途。

公开(公告)号：US07343386B2

公开(公告)日：2008-03-11

申请号：US11048001

申请日：2005-01-31

申请人： José Gomes ,  Man Mohan Singh ,  Mila Keren ,  Sai Zeng ,  Julia Rubin ,  Laurent Balmelli ,  Ioana Boier-Martin

发明人： José Gomes ,  Man Mohan Singh ,  Mila Keren ,  Sai Zeng ,  Julia Rubin ,  Laurent Balmelli ,  Ioana Boier-Martin

IPC分类号： G06F17/30

CPC分类号： G06F17/24 ,  G06Q10/10 ,  Y10S707/99953 ,  Y10S707/99954

摘要： A plurality of artifacts, in a plurality of repositories, are maintained under revision control. A plurality of artifact tuples, in another repository, are maintained under revision control. At least one first artifact tuple comprise first information providing access to at least one of the artifacts. At least one second artifact tuple comprises second information providing access to at least one other artifact tuple. Each of the artifact tuples are associated with at least one of a plurality of product development processes. An apparatus comprises a plurality of repositories, each maintaining under revision control a plurality of artifacts and another repository that maintains under revision control a plurality of artifact tuples. A workflow process is adapted to allow users to associate each of the artifact tuples with at least one of a plurality of product development processes.

摘要翻译： 在多个仓库中的多个工件保持在修订控制下。 在另一个存储库中的多个伪像元组被维护在版本控制之下。 至少一个第一伪像元组包括提供对至少一个伪像的访问的第一信息。 至少一个第二伪像元组包括提供对至少一个其他伪像元组的访问的第二信息。 每个工件元组与多个产品开发过程中的至少一个相关联。 一种装置包括多个存储库，每个存储库都在修订控制下维护多个工件，另一个存储库维护着许多伪影元组的版本控制。 工作流过程适于允许用户将每个工件元组与多个产品开发过程中的至少一个相关联。

公开(公告)号：US20090083711A1

公开(公告)日：2009-03-26

申请号：US11862171

申请日：2007-09-26

申请人： Man Mohan Singh ,  Sai Zeng ,  Jose Gomes ,  Ioana Boier-Martin

发明人： Man Mohan Singh ,  Sai Zeng ,  Jose Gomes ,  Ioana Boier-Martin

IPC分类号： G06F9/44

CPC分类号： G06F8/71

摘要： A computer-implemented method supporting collaborative product development. A plurality of artifacts associated with the collaborative product development is maintained under revision control in a first repository. Each artifact has a plurality of lifecycle states and each artifact is associated with a first finite state machine (FSM) that defines lifecycle state transitions for the artifacts. A plurality of artifact tuples associated with the collaborative product development is maintained under revision control in a second repository. At least one artifact tuple is comprised of at least one access information providing access to at least one of said plurality of artifacts in the first repository. Each artifact tuple has a plurality of lifecycle states and each artifact tuple is associated with a second finite state machine (FSM) that defines lifecycle state transitions for the artifact tuples. There exists a set of lifecycle state transition mappings which maps all valid lifecycle state transitions for an artifact with desired lifecycle state transitions for an artifact tuple and all valid lifecycle state transitions for an artifact tuple with desired lifecycle state transitions for an artifact. A workflow process relating to an evolution of an artifact or artifact tuple is expressed through sequencing of one or more members of the said lifecycle state transition mappings set.

摘要翻译： 支持协同产品开发的计算机实现方法。 与协作产品开发相关联的多个工件在第一仓库中被维护在版本控制下。 每个工件具有多个生命周期状态，并且每个工件与定义工件的生命周期状态转换的第一有限状态机（FSM）相关联。 与协作产品开发相关联的多个伪像元组在第二存储库中被维护在版本控制下。 至少一个工件元组由至少一个访问信息组成，提供对第一存储库中的所述多个工件中的至少一个工件的访问。 每个工件元组具有多个生命周期状态，并且每个工件元组与定义人造元组的生命周期状态转换的第二有限状态机（FSM）相关联。 存在一组生命周期状态转换映射，它将工件的所有有效生命周期状态转换与工件元组的所需生命周期状态转换和工件的所有生命周期状态转换的工件元组的所有有效生命周期状态转换进行映射。 通过对所述生命周期状态转换映射集合中的一个或多个成员的排序来表示与工件或伪像元组的演进有关的工作流过程。

公开(公告)号：US20080046472A1

公开(公告)日：2008-02-21

申请号：US11926781

申请日：2007-10-29

申请人： Jose Gomes ,  Man Mohan Singh ,  Mila Keren ,  Sai Zeng ,  Julia Rubin ,  Laurent Balmelli ,  Ioana Boier-Martin

发明人： Jose Gomes ,  Man Mohan Singh ,  Mila Keren ,  Sai Zeng ,  Julia Rubin ,  Laurent Balmelli ,  Ioana Boier-Martin

IPC分类号： G06F17/30

CPC分类号： G06F17/24 ,  G06Q10/10 ,  Y10S707/99953 ,  Y10S707/99954

摘要： A plurality of artifacts, in a plurality of repositories, are maintained under revision control. A plurality of artifact tuples, in another repository, are maintained under revision control. At least one first artifact tuple comprise first information providing access to at least one of the artifacts. At least one second artifact tuple comprises second information providing access to at least one other artifact tuple. Each of the artifact tuples are associated with at least one of a plurality of product development processes. An apparatus comprises a plurality of repositories, each maintaining under revision control a plurality of artifacts and another repository that maintains under revision control a plurality of artifact tuples. A workflow process is adapted to allow users to associate each of the artifact tuples with at least one of a plurality of product development processes.

摘要翻译： 在多个仓库中的多个工件保持在修订控制下。 在另一个存储库中的多个伪像元组被维护在版本控制之下。 至少一个第一伪像元组包括提供对至少一个伪像的访问的第一信息。 至少一个第二伪像元组包括提供对至少一个其他伪像元组的访问的第二信息。 每个工件元组与多个产品开发过程中的至少一个相关联。 一种装置包括多个存储库，每个存储库都在修订控制下维护多个工件，另一个存储库维护着许多伪影元组的版本控制。 工作流过程适于允许用户将每个工件元组与多个产品开发过程中的至少一个相关联。